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10.1  Introduction 
Cigarette smoking is associated with such life-threatening illnesses as 
cancer, ischemic heart disease, cerebrovascular disease, and chronic lung 
disease. Smoking contributes not only to lung cancer but also to cancers of 
the pharynx, esophagus, bladder, and many others. It  is reported that com- 
plications of pregnancy, including low birth weight and miscarriage, are re- 
lated to smoking. Passive smoking is also a risk factor for such diseases. 
Cigarette smoking is one of the most serious causes of premature mortal- 
ity in Japan. Researchers have estimated that about 113,400 Japanese die 
annually due to smoking-related illnesses, which accounts for 11.8 percent 
of total deaths (Peto et al. 2004). Estimates of excess medical costs per year 
due to smoking-related disease range from 1.2  trillion (Institute for Health 
Economics and Policy 1997) to 3.2 trillion yen (Goto 1995, 1996),' or from 
5 to 15 percent of national medical expenditures. 
In response to the escalating national health care costs, particularly 
those of lifestyle-related diseases, smoking cessation has become one of the 
most important national health policy objectives. The Ministry of Health, 
Labor and Welfare established the Committee on Tobacco Control for 
the 21st Century in the year 2000 and was committed to a national no- 
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1. It has been estimated that the total social loss including lost gross national product 
(GNP) as well as medical expenses amounted to between 4 trillion (Institute for Health Eco- 
nomics and Policy 1997) and 5.6 trillion yen (Goto 1995, 1996). 
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smoking-week campaign. The ministry also established as an objective the 
provision of support to help smokers stop smoking in all communities. The 
Japanese Medical Association has also conducted an antismoking cam- 
paign since year 200 1. 
A significant proportion of smokers seriously consider quitting smok- 
ing. For example, according to the Survey on Smoking and Health Prob- 
lems in 1998 by the Japanese government, 26.7 percent of current smokers 
aged fifteen and over want to quit smoking, and 64.2 percent of them want 
to quit smoking or cut down smoking. However, only a small fraction of 
them actually succeed on their own, due to the addictive nature of nicotine 
(US. Department  of  Health  and Human  Services 1988, 1995, 1996a; 
WHO 1993). Recently, however, smoking intervention programs, particu- 
larly those using nicotine replacement therapy (NRT), have been shown to 
be very effective in other countries, such as the United States. 
Nicotine replacement therapy is a method of treatment that helps smok- 
ers by alleviating the withdrawal symptoms associated with smoking ces- 
sation by replacing the nicotine. Researchers have shown that 17 to 50 per- 
cent of smokers have succeeded in smoking cessation using those therapies 
(Momma  1998; Asano 2000; Wasley et al.  1997; Jorenby  et al.  1999; 
Schneider, Jarvik, and Forsythe  1984). Two types of NRT products are 
available in Japan, nicotine transdermal patches and nicotine gum. Nico- 
tine patches were approved by the Ministry of Health and Welfare in 1994, 
and nicotine gums were approved in  1999. Despite the effectiveness of 
those products, they have failed to come into wide use in Japan, as they 
have been available only by prescription, and their costs have not been cov- 
ered by the public health insurance. 
The government has done nothing to inform the smokers of the avail- 
ability of NRT, and there were few medical professionals who could give 
counseling or other therapies for smoking cessation. Things changed com- 
pletely in September 2001 when the Ministry of Health and Welfare, under 
the strong pressure to show concrete results of deregulation in health care 
sector, approved nicotine gum (brand name Nicorette) as an over-the- 
counter drug. There immediately followed an extensive nationwide cam- 
paign by the pharmaceutical company using TV, newspapers, and maga- 
zines. As a result, Nicorette is now widely recognized among smokers as 
well as nonsmokers. 
In this paper, we estimate the demand for nicotine gum and examine the 
smoking cessation assistance policy with NRT using original survey data 
gathered by the authors in late 2001. Our analysis is the first attempt to es- 
timate the demand for NRT in Japan. Tauras and Chaloupka (2001) as- 
sessed the impact of NRT prices and cigarette prices on NRT demand us- 
ing pooled cross-sectional-time  series data for fifty major metropolitan 
markets in the United States from 1996 to 1999. We could not employ a 
similar technique because panel data are not available in Japan; nicotine Conjoint Analysis of Demand for Nicotine Replacement Therapy in Japan  231 
gum has been in the market for a relatively short period of time, and do- 
mestic cigarette prices are uniformly set throughout Japan. Therefore, we 
employed conjoint analysis (CA), a technique that is relatively new to the 
field of health economics. 
Conjoint analysis is one of the techniques belonging to contingent valu- 
ation methods (CVM) used to estimate an individual’s utilities from re- 
sponses to hypothetical questions. Conjoint analysis was originally devel- 
oped in the field of market research and psychometrics. It has been widely 
used in environmental economics and transport economics, and it has 
been introduced into health economics.*  In Japan, CA has been used to es- 
timate the demand for nursing care (Suzuki and Okusa 1999), the choice of 
medical facilities (Fukuda et al. 1999),  and the demand for medical care for 
minor illness (Suzuki and Okusa 2000). 
The stages of CA are detailed as follows. First, hypothetical scenarios 
and discrete choice questionnaires are presented to individuals. After indi- 
viduals state their preference, the responses are used to determine utilities. 
A statistical model is constructed using the hypothetical scenarios and the 
characteristics of respondents as explanatory variables and stated prefer- 
ences as the dependent variable. Then the utility function and rate of sub- 
stitution are calculated. 
The methodologies commonly utilized to assess individuals’ utilities in 
health economics have been the standard gamble, time trade-off, and rat- 
ing scale as well as willingness to pay. These traditional approaches have 
both theoretical and technical problems. The price obtained from willing- 
ness to pay does not properly reflect the real utility level. None of usual ap- 
proaches-standard  gamble, time trade-off, and rating scale-can  capture 
the utility level very well. When we deal with ordinal utility, it can be prob- 
lematic to compare and add up utility levels among individuals. Unlike 
these four techniques, CA uses questionnaires asking individuals about 
their relative preferences instead of directly asking their utility level. There- 
fore, it can avoid the problem faced by the other methods. Conjoint anal- 
ysis is also advantageous in that unobservable factors related to the indi- 
vidual can be eliminated as an individual effect. 
The remainder of the paper is organized as follows. In section 10.2, the 
data used  for this study are described. Descriptive statistics regarding 
smoking and awareness of nicotine gum are also provided in this section. 
In section 10.3, the methods and results using CA are presented. The ap- 
plication of the estimates from CA to cost-benefit analysis is demonstrated 
in section 10.4. We compare the costs and benefits of a hypothetical sub- 
sidy for nicotine gum. Section 10.5 concludes. 
2. For examples, see Bryan et al. (1998), Freeman (1998), Hakim and Pathak (1999), Rat- 
cliffe and Buxton (1999), Ryan (1999), Ryan and Farrar (1994), Ryan and Hughes (1997), 
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Table 10.1  Descriptive statistics 
Standard 
N  Mean  deviation  Minimum  Maximum 
Age of smoking initiation 
Years of smoking 






Logged annual income 
Number of family 
Heart disease 
Diabetes 
Disease of circulatory system 






























0.4841  52 
13.249  15 
0.50041  9 
399.5757 
0.6582189 






























Nutes: Years of smoking is derived by subtracting age of smoking started from current age. The FTND 
index is an epidemiological index that measures the level of nicotine dependence (see note in the paper). 
Annual income is in ten thousands of yen. Education was coded 1 if finished postcollegiate, college, or 
junior college, 0 otherwise. Each chronic illness was coded 1 if there is any, 0 otherwise. 
Table 10.2  Desire for smoking cessation 
N  Percent 
In the process  36  7.2 
Don’t want to quit  226  45.1 
Want to but haven’t done anything  239  47.7 
10.2  Data 
The data were collected using the Survey on Smoking that the authors 
conducted in November 2001. The questionnaire was mailed to 500 smok- 
ers aged twenty to sixty-nine who were residing in the Tokyo metropolitan 
area. They were selected from a list of monitors who had registered with a 
private research firm. The firm randomly selected their monitors from a na- 
tional resident-registry list.3  The response rate was 83.3 percent. The char- 
acteristics of individuals included in the analysis are presented in table 10.1. 
The survey asked  the  respondents  about  their  attitude  toward  and 
awareness of smoking cessation and nicotine gum before presenting the hy- 
pothetical scenarios. Table 10.2 indicates the attitude toward smoking ces- 
3. It is possible that sample bias arose when people decided whether to be a monitor, but 
the social research firm made efforts to make the bias as small as possible by adjusting the 
sample to represent the census distribution in terms of age and other characteristics. Con-joint  Analysis of Demand for Nicotine Replacement Therapy in Japan  233 
Table 10.3  A means of smoking cessation 
Smokers who 
Smokers who  attempted smoking 
want to quit  cessation 
N  Percent  N  Percent 
Don’t use anything  198  72.5  27  75.0 
Counseling by 
Nicorette  63  23.1  8  22.2 
Other  12  4.4  1  2.8 
medical professionals  0  0.0 
Table 10.4  Recognition of Nicorette 
N  Percent 
Know of Nicorette  350  70.14 
Don’t know of Nicorette  149  29.86 
Table 10.5  Opinion of the price of Nicorette 
N  Percent 
Expensive  398  79.8 
Appropriate  89  17.8 
Inexpensive  12  2.4 
sation among smokers. Of  particular interest is the fact that 7 percent of 
smokers were attempting to quit, and 48 percent were contemplating quit- 
ting. Thus, more than half of smokers in our sample want to quit smoking. 
The methods of smoking cessation are presented in table 10.3. Among the 
smokers who want to quit smoking, a large majority of them (72.5 percent) 
did not plan to use any particular device or help, but almost one-quarter 
(23.1 percent) of them mentioned nicotine gum as a device. There were 
eight respondents who were actually using the nicotine gum, which repre- 
sents 22.2 percent of those who were actually trying to quit smoking. Table 
10.4  shows that already 70.1 percent of respondents were aware of the nico- 
tine gum, and it is clear that the nicotine gum has become widely known, 
at least in the Tokyo metropolitan area, in a very short period of time after 
it was introduced into the market. However, nearly 80 percent of respon- 
dents viewed Nicorette as expensive, as table 10.5  As a result, only 
4. The price was 6,900 yen for sixty pieces and 36,000 yen for a course of smoking cessa- 
tion. The authors estimated the cost of a course of smoking cessation based on the directions 
for use and the price from Nicorette’s homepage (http://www.nicorette-j.com/). 234  Seiritsu Ogura, Wataru Suzuki, Makoto Kawamura, and Tamotsu Kadoda 
13.5 percent of respondents were willing to use nicotine gum (table 10.6). 
We also asked for the reason they were not going to use the gum among 
those who answered “interested but won’t use” or “not interested.” About 
50 percent of them answered that the nicotine gum was expensive. This 
suggests that the high price is preventing the diffusion of the nicotine gum. 
10.3  Estimation of Demand for Nicotine Gum 
10.3.1  Estimation Model 
The questionnaires used for CV are presented in table 10.7. Respondents 
were asked to circle 1 or 2 for each scenario, which indicated “use nicotine 
gum” and “not use nicotine gum,” respectively. The factors that varied 
across scenarios were the price of nicotine gum, the price of cigarettes, and 
access to nicotine gum. Several levels were assigned for each attribute. Two 
different prices were assigned for the nicotine gum: its current price and 
half the current price. Three different prices were assigned for cigarettes: 
the current price, double the current price, and five times the current price. 
Two levels of access were used: status quo and being able to get the gum at 
Table 10.6  Interest in Nicorette 
N  Percent 
Want to use  61  13.5 
Interested but won’t use soon  24 1  48.5 
Not interested  189  38.0 
Table 10.7  Hypothetical scenarios 
If Nicorette is sold at half-price (3,450 yen for 60 tablets; 18,000 yen for a course of smoking 
If Nicorette is sold at half-price and available at a vending machine or at a convenience store 
If Nicorette is sold at half-price while tobacco price is doubled (about 500 yen a box) 
If Nicorette is sold at half-price while tobacco price is raised to five times as much as current 
If Nicorette is sold at half-price and available at a vending machine or at a convenience store 
If Nicorette’s price stays the same (6,900 yen for 60 tablets; 3,600 yen for a course of smoking 
If Nicorette’s price stays the same while tobacco price is doubled 
If Nicorette’s price stays the same while tobacco price is raised to five times as much as 
current price 
If Nicorette’s price stays the same and Nicorette is available at a vending machine or at a 
convenience store while tobacco price is doubled 
If Nicorette’s price stays the same and Nicorette is available at a vending machine or at a 
convenience store while tobacco price is raised to five times as much as current price 
cessation) 
price 
while tobacco price is raised to five times as much as current price 
cessation) but available at a vending machine or at a convenience store Conjoint Analysis of Demand for Nicotine Replacement Therapy in Japan  235 
a vending machine or at a convenience store. The combination of attributes 
and levels resulted in eleven possible scenarios (2 X 3 X 2 -  1). 
The estimation equation is as follows: 
GTk = a. + a,&  + a,T,,  + OL~R,,~  + a&  + ayy  + a$, + aAAt  + &,EL 
+  log 4 +  OlJ  'I,,  + 'i,k 
1  if  GTk >  0 
Gl,k =  otherwise 
'i,k  =  '~,k  +  't7 
where Gt,k  is a latent variable, which is a difference between the utility from 
quitting smoking with the nicotine gum and the utility from keeping smok- 
ing without it. Explanatory variables were defined as follows:  <,k  is price of 
nicotine gum; T,k  is price of cigarettes; Rl,k  represents whether nicotine gum 
is available at a vending machine or at a convenience store (1 if available, 0 
otherwise); eis  the FTND index;s xis  years of smoking; Az  is age; S,  is sex 
(1 if male, 0 if female); El is categorized years of education (1 ifjunior col- 
lege or more, 0 otherwise); log I,  is logged annual income; J,,,  is a vector of 
chronic illnesses (1 if they have, 0 otherwise); and y  is health status (1 if in 
bad health, 0 otherwise). We employed a random effect probit model (But- 
ler and Moffitt, 1982) because we assumed that an individual had consis- 
tent effects regardless of scenarios. We assumed that the individual effect, 
uz,  was normally distributed as follows: 
UZ  -  N(0,  a:> 
10.3.2  Results 
Table 10.8 reports the results of the estimation. The coefficients of the 
three policy instruments had the expected signs. The price of nicotine gum 
had a negative effect on nicotine gum purchase, the price of cigarettes had 
a positive effect, and access to the gum had positive effects on nicotine gum 
purchase.  Other statistically significant explanatory variables were the 
Fagerstrom Test for Nicotine Dependence (FTND) index, years of smok- 
ing, sex, education, log of  annual income, and circulatory  illness. The 
higher FTND index made the nicotine gum demand higher. The more 
years of smoking, the higher the demand for the gum. Women, people with 
higher income, and people with higher levels of education had higher de- 
5. The nicotine dependence index developed by Dr. Fagerstrom was derived from a short 
paper-and-pencil test (Fagerstrom and Schneider 1989). We employed a revised Fagerstrom 
Test for Nicotine Dependence index (FTND  index) for this study. The actual test is presented 
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Table 10.8  Profit estimates for NRT demand 
Standard 
Coefficient  error  p-value 
Nicorette price 
Tobacco price 
Vending machine or convenience store 
FTND index 







Disease of circulatory system 
Disease of digestive system 
Constant 
-0.8379*** 









































Notes: Nicorette price is in  10,000 yen, and tobacco price is in yen. The number of total 
samples is 5,820 (485 individuals are included). Log likelihood = -2065.8625. 
***Significant at the 1 percent level. 
**Significant at the 5 percent level. 
*Significant at the 10 percent level. 
mand for nicotine gum. People with circulatory disease also had higher de- 
mand. 
Table 10.9 shows the marginal effect of each attribute. The results indi- 
cate that a 10,000 yen (27.8 percent) decrease in the price of nicotine gum 
would increase its own demand by  16.5 percent, and a 100 yen (40.0 per- 
cent) increase in the price of cigarettes would lead to an increase of 4.2 per- 
cent in the demand for nicotine gum. It is also revealed that if nicotine gum 
is made available at a vending machine or a convenience store, the demand 
for the gum would increase by 3.3 percent. 
Our estimation  results  are basically consistent  with  the  findings of 
Tauras and Chaloupka (2001) that show that the price of nicotine gum has 
a negative effect on its demand, while the price of cigarettes has a positive 
effect.6  Specifically,  using pooled cross-sectional-time-series observational 
data for fifty major metropolitan markets in the United States, Tauras and 
Chaloupka showed that the average own-price elasticity of demand for 
nicotine gum is -1  -5, while the average cross-price elasticity for cigarettes 
is 0.81, which is several times larger in magnitude than our estimates of 
-0.59  and 0.1 I,  respectively. These differences in price elasticities could be 
6. Keeler et al. (2002), however, find that the impact of the price of nicotine gum on demand 
is not statistically significant in the United States. Conjoint Analysis of Demand for Nicotine Replacement Therapy in Japan  237 
Table 10.9  Marginal effects 
Standard 
Coefficient  error  p-value 
Nicorette price 
Tobacco price 
Vending machine or convenience store" 
FTND  Index 







Disease of circulatory system" 
Disease of digestive system" 
-0.1652*** 






































Note: Nicorette price is in 10,000 yen, and tobacco price is in yen. Standard errors are calcu- 
lated by Delta method. 
*dy/dx  is for discrete change of dummy variable from 0 to 1. 
***Significant at the 1 percent level. 
**Significant at the 5 percent level. 
*Significant at the 10 percent level. 
due to the difference in the nature of the data used for the analyses; where 
they use aggregate market data, we use microconjoint data. 
10.4  Cost-Benefit Analysis for a Smoking Cessation Support Policy 
Nicotine replacement therapy is costly to the individual because it is not 
paid for by health insurance, whether it is prescribed or purchased over the 
counter. We  examine whether  a government subsidy for nicotine  gum 
would make NRT more available to people who want to quit smoking. 
Many epidemiological studies have shown that among ex-smokers, dis- 
ease incidence decreases dramatically up until five years after smoking 
cessation and continues to drop thereafter, eventually reaching the same 
level as nonsmokers after ten to fifteen years (U.S.  Department of Health 
and Human Services 1990,1996b; Hirayama 1987; Hirayama 1990).  If the 
benefits from  smoking  cessation  go  only to smokers,  they  should  be 
responsible for all the costs associated with NRT. However, Japan has a 
universal health insurance system, which covers 70 percent of medical ex- 
penses, and the nation as a policyholder shares the cost of supporting the 
health insurance system. If nicotine gum helps to reduce national medical 
expenditures and health insurance payments, the benefits are considered 
externalities. In such a case, it could make sense to introduce a subsidy for 
the nicotine gum. Specifically, we wish to examine how the costs of a sub- 238  Seiritsu Ogura, Wataru Suzuki, Makoto Kawamura, and Tamotsu Kadoda 
Table 10.10  Equations for cost-benefit analysis 
Total costs 
Total cost = A (Subsidy per capita) . B (Increased number of smokers who demand the gum 
after the policy) 
A = Average cost for a course of smoking cessation . Subsidy rate (70%) 
B = C (Estimated number of smokers) . D (Increased demand ratio due to the 
D = Estimated demand elasticity (0.16) .  A 
policy) 
Yearly benejts 
Yearly benefits = E (Number of smokers who would succeed in smoking cession with policy) 
.  F (Reduced annual insurance payment) 
E = B . Success rate by nicotine gum 
F = G (Excess health insurance payment per smoker) . H (Rate of medical 
expense reduction by smoking cessation) 
G = Excess annual medical expenditure due to smoking . Health insurance 
coverage rate (0.7)/C 
H = (Mortality of smokers  ~  Mortality of former smokers)/(Mortality of 
smokers  ~  Mortality of nonsmokers) = (Excess mortality of smokers 
Excess mortality of former smokers)/Excess  mortality of smokers 
Note: Average cost for a course of smoking cessation: 36,000 yen (authors’ calculations based 
upon an explanatory note on the product). Subsidy rate: 0.7. Estimated number of smokers: 
33.6 millions (Ministry of Health and Welfare 1999). Estimated price elasticity of demand: 
0.16 (table 10.8). Excess annual medical expenditure due to smoking: 1.2 trillion yen (Insti- 
tute for Health Economics and Policy 1997). Health insurance coverage rate: 0.7. Success rate 
by nicotine gum: 23% (Asano 2000). Excess mortality of smokers: 23% (Hirayama 1987). 
sidy compare to the benefits associated with a reduction in health insur- 
ance payments. 
Therefore, we have estimated the costs and the benefits associated with 
the subsidy policy and conducted a cost-benefit analysis. We assumed the 
subsidy rate to be 70 percent. This was appropriate because if the nicotine 
gum is covered with health insurance, the coverage rate would be 70 per- 
cent.7  Equations for costs and benefits are presented in table 10.10. 
10.4.1  Total Cost 
The total cost was calculated by multiplying the subsidy per smoker by 
the increased number of smokers who demand the nicotine gum due to the 
policy. The subsidy per smoker is the product of the average cost for a 
course of smoking cessation (36,000 yen) and subsidy rate (70 percent). 
The increased number of smokers demanding the nicotine gum after the 
policy is the product of the estimated number of smokers and increased de- 
mand ratio due to the policy (equation [3]).  The increased demand ratio 
due to the policy was derived from the estimates presented in table 10.8. 
According to the CA results, a 10,000 yen downward shift in the price of a 
7. Our assumption is not that insurance coverage would pay 70 percent of the cost, but 
rather that a subsidy would reduce the price to 30 percent of the current price. Conjoint Analysis of Demand for Nicotine Replacement Therapy in Japan  239 
course of treatment is to reduce the demand response by  16 percent. The 
cost reduction due to the subsidy was 25,200 yen (36,000 yen X 0.7). There- 
fore, the increased demand ratio due to the policy was 0.40 (D in table 10.10). 
10.4.2  Yearly Benefit 
The yearly benefit is a product of the number of smokers who succeeded 
in quitting smoking after the policy and the reduced annual insurance pay- 
ments due to the policy (E . F in table 10.10). The number of smokers who 
succeeded in quitting smoking after the policy is derived by multiplying the 
increased number of smokers demanding the nicotine gum after the policy 
by the success rate for smoking cessation with the nicotine gum (E in table 
10.10). The success rate used in this estimation was 23 percent, which is 
the mean value from epidemiological studies conducted in Japan (Asano 
2000). It is conservative compared to other studies on NRT. The reduced 
annual insurance payment is, as F in table 10.10 shows, the product of the 
excess health insurance payment per smoker and the rate of medical ex- 
pense reduction from smoking cessation. The excess health insurance pay- 
ment per smoker was derived by dividing the product of excess annual med- 
ical expenditure due to smoking (1.2 trillion yen) and health insurance 
coverage rate (0.7) by the estimated number of smokers (33.6 millions). The 
1.2 trillion yen as excess annual medical expenditures is quite moderate, 
and the actual insurance coverage rate is more than 70 percent. Therefore, 
the values we used are considered very conservative. We multiplied excess 
health insurance payment per smoker by the rate of medical expense re- 
duction rate due to smoking cessation in order to adjust the effect of smok- 
ing cessation on medical expenses, which  was not exactly the same as 
among nonsmokers. According to Hirayama’s study (1987), excess mortal- 
ity of smokers and excess mortality of former smokers were 23 percent and 
4 percent, respectively. We employed these numbers. We divided the differ- 
ence between 23 percent and 4 percent by 23 percent, then obtained the rate 
of medical expense reduction due to smoking cessation, which is 82 percent. 
10.4.3  Cost-Benefit 
Consequently the subsidy would cost the government a total of 352.4 bil- 
lion yen, and the benefits due to the reduction of health insurance payment 
would be 67.6 billion yen per year. The benefits would be ongoing even if 
the subsidy were offered only once. After five years, the government would 
be able to save 338.5 billion yen (67.6 billion X 5), which is approximately 
equal to the cost. Given that the benefits could continue for longer than five 
years, it is highly possible that the benefits of the subsidy policy could meet 
all of the costs. 
10.4.4  Other Factors to Be Considered as Long-Run Effects 
The cost-benefit analysis in this section was conducted with very limited 
information, so it cannot be overemphasized that various other factors 240  Seiritsu Ogura, Wataru Suzuki, Makoto Kawamura, and Tamotsu Kadoda 
Health Insurance Payment 
/ 
Health Capital 
Smokers' Age  Non-smokers' 
at Death  Age at Death 
Smokers' Age  Non-smokers' 
at Death  Age at Death 
Fig. 10.1  Lifetime health insurance payment and health capital by smoking status 
should be taken into consideration for a more precise analysis. One of the 
most important factors is the part of the health insurance payment corre- 
sponding to the life extended by smoking cessation. The concept is shown 
in the upper part of figure 10.1. It illustrates the insurance payment that in- 
creases with age. The lifetime insurance payments of smokers are shown by 
the area of A + B. The area of B is an insurance payment that is common 
to both smokers and nonsmokers, and the area of A is a smoker's addi- 
tional health insurance payment due to health problems. The decrease in 
the area of A due to smoking cessation represents cost savings. On the 
other hand, the area of C would be added to costs when the length of life is 
extended. Therefore, net benefits should be calculated by subtracting the 
area of C from the area of A. 
In order to compute the area of C, two numerical values are required. 
One is the difference between the average life expectancy among smokers 
versus nonsmokers. The other is medical expenses associated with lon- 
gevity. The first number is, unfortunately, unavailable in Japan, but it has 
been estimated in various countries. The median longevity effect is eight 
years (Simpson ZOOO),  and we used this number. As for the extra medical 
expense, it is not overwhelming according to the research by Suzuki and 
8. Suzuki and Suzuki (2003) decomposed the medical expenses for the aged into the ordi- 
nal care and the terminal care as Lubitz, Beebe, and Baker (1995) did. Conjoint Analysis of Demand for Nicotine Replacement Therapy in Japan  241 
Suzuki (2003).8  Living eight more years makes medical expenses increase 
only by 3.94 million yen per person because most of the medical expendi- 
ture for the old is accounted for by terminal care. We multiplied this 3.94 
million yen increase in the insurance payment by 78 million people, which 
is the number of successful ex-smokers, and obtained the cost presented in 
the area of C, which is 3,073 billion yen. 
The other possible benefit is the increased health capital due to longevity 
(see figure 10.1). Health capital is a monetary value of life that takes health 
into consideration. It is defined as follows: 
a  E(Hk) 
k=O  (1 + ry  ’ 
health capital = Vc  ~ 
where  I/ is the value of the life, which is normally lifetime earnings. Hk is 
quality of life factor for a year at age k;  and  Y is real discount rate. The value 
of health capital was estimated by Cutler and Richardson (1997, 1998) in 
the United States and by Fukui and Iwamoto (2003) in Japan. We can take 
sum of the implied quality of life age factor from Fukui and Iwamoto 
(2003) and lifetime earnings (280 million yen) from the Economic Surveys 
of Japan in 1990. Using a 3 percent real discount rate, like Cutler and 
Richardson, the benefit associated with an eight-year increase in health 
capital was 8.54 million yen per person. We multiplied the 8.54 increase in 
health capital by 78 million people and obtained the benefit represented 
by the area of E, which is 6,670 billion yen. As a result, the area of C sub- 
tracted from E, which is the net benefit associated with the lengthened life, 
amounts to 3,300 billion yen. 
10.5  Conclusions 
This paper estimates the demand function for nicotine gum (Nicorette) 
that has been on the market since it was approved as an over-the-counter 
drug in September 2001. The estimate obtained from conjoint analysis in- 
dicates that a 10,000 yen decrease in the price of nicotine gum would in- 
crease the demand for the gum by 16.5 percent, and a 100 yen increase in 
the price of cigarettes would lead to an increase in the demand for nicotine 
gum of 4.2 percent. It is also estimated that if nicotine gum were made 
available at a vending machine or a convenience store, the demand for 
nicotine gum would increase by 3.3 percent. 
A cost-benefit analysis was conducted to estimate the consequence of a 
subsidy policy for nicotine gum. In the case of a 70 percent subsidy for 
nicotine gum, it would cost the government 352.4 billion yen. The benefits 
associated with the subsidy are a decrease in smoking-related illnesses 
through successful smoking cessation. This would make annual medical 
insurance payment fall by 67.6 billion yen. After five years, the government 
would save 338.5 billion yen, which is comparable to the cost. 242  Seiritsu Ogura, Wataru Suzuki, Makoto Kawamura, and Tamotsu Kadoda 
When we  take the change in the lifetime medical insurance payments 
and health capital accumulation into account, 3,300 billion yen should be 
added to the benefits in the long run. 
The Ministry of Health, Labor and Welfare initiated the national health 
promotion movement so-called Healthy Japan 21 in the year 2000 and es- 
tablished smoking cessation promotion as one of the most important pol- 
icy objectives. A subsidy for nicotine gum or insurance coverage for the 
gum is one possible means of achieving the public health goal. 
It is worth noting that the costs and benefits that this study used were 
based on a demand function estimated using CA, which does not necessar- 
ily represent the actual demand fun~tion.~  The net values of CBA should, 
therefore, be carefully examined. Furthermore, when real transaction data 
eventually become available, the demand function  should be calculated 
with the real values, and the total costs and benefits should be reexamined. 
Appendix 
Table 10A.l  Fagerstrom Test for Nicotine Dependence Index 
Questions  Answers  Points 
1.  How soon after you wake up do you 
smoke your first cigarette? 
2. Do you find it difficult to refrain from 
smoking in places where it is forbidden? 
(e.g., in library, in movie theater) 
to give up? 
3. Which cigarette would you most hate 
4. How many cigarettes a day do you smoke? 
5. Do you smoke more frequently during 
the first hours after awakening than during 
the rest of the day? 
are in bed most of the day? 
6. Do you smoke if you are so ill that you 
Within 5 minutes 
Within 6-30  minutes 
Within 31-60  minutes 
After 60 minutes 
Yes 
No 
The first one in the morning 
Any other 
3 1 or more 
21-30 
11-20 





















9. Suzuki and Okusa (2000) evaluated the magnitude of the bias in CA by comparing the 
demand function from CA to the actual demand function calculated from transaction data. 
Tsuji and Suzuki (2002) measured the bias in CVM. Conjoint analysis has relatively small bias 
compared to other hypothetical market methods, but there is still a discrepancy with the real 
value. Further research should explore methods to lessen the bias. Conjoint Analysis of Demand for Nicotine Replacement Therapy in Japan  243 
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